Insider: Sullivan Timothy Eugene Chief Financial Officer - Apellis Pharmaceuticals, Inc.
| Company Holdings |
| Direct | Indirect Ownership | Total | |
| Shares | 110,936 | 60,396 | 171,332 |
| Value | $2,481,638.32 | $1,351,058.52 | $3,832,696.84 |
Trans. Date |
Trans. Type |
Shares |
Ownership Type |
Issue Type |
Price |
Trans. Value |
Total Shares Owned |
|---|---|---|---|---|---|---|---|
| 09/08/2025 | DDS | 10,000 | Indirect | COM | $27.83 | $278,300.00 | 60,396 |
| 09/08/2025 | DDS | 32,729 | Direct | COM | $27.86 | $911,829.94 | 110,936 |
| 01/29/2025 | DDS | 546 | Direct | COM | $29.52 | $16,119.89 | 128,665 |
| 01/22/2025 | DDS | 3,088 | Direct | COM | $30.43 | $93,953.94 | 129,211 |
| 01/17/2025 | DDS | 1,730 | Direct | COM | $29.96 | $51,827.69 | 86,370 |
| 01/13/2025 | DDS | 2,170 | Direct | COM | $28.70 | $62,283.56 | 88,100 |
| 04/01/2024 | DDS | 4,000 | Direct | COM | $58.66 | $234,640.00 | 93,338 |
| 03/01/2024 | DDS | 4,000 | Direct | COM | $62.86 | $251,440.00 | 95,338 |
| 03/01/2024 | DDS | 2,000 | Direct | COM | $63.95 | $127,900.00 | 93,338 |
| 02/12/2024 | DDS | 1,431 | Direct | COM | $67.77 | $96,974.43 | 93,338 |
| 01/29/2024 | DDS | 906 | Direct | COM | $64.14 | $58,109.21 | 94,769 |
| 01/22/2024 | DDS | 3,551 | Direct | COM | $65.00 | $230,800.80 | 95,675 |
| 01/16/2024 | DDS | 2,235 | Direct | COM | $66.81 | $149,317.22 | 99,226 |
| 11/30/2023 | DDS | 13,858 | Direct | COM | $54.73 | $758,448.34 | 78,013 |
| 11/30/2023 | DDS | 300 | Direct | COM | $54.79 | $16,435.98 | 77,713 |
| 06/05/2023 | DDS | 1,600 | Direct | COM | $90.60 | $144,967.04 | 145,892 |
| 06/05/2023 | DDS | 30,609 | Direct | COM | $87.79 | $2,687,121.26 | 115,283 |
| 06/05/2023 | DDS | 7,064 | Direct | COM | $88.36 | $624,209.65 | 108,219 |
| 06/05/2023 | DDS | 30,506 | Direct | COM | $89.83 | $2,740,228.91 | 77,713 |
| 08/29/2019 | AAP | 11,699 | Direct | COM | $29.71 | $347,629.94 | 11,699 |
| 1 You are at page 1 of 1 pages |
|
Transaction Type Key First letter: A = Acquired, D = Disposed Second letter: A = Grant, award or other acquisition pursuant to Rule 16b-3(d) C = Conversion of derivative security | D = Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | E = Expiration of short derivative position | F = Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. | G = Gift | H = Expiration (or cancellation) of long derivative position with value received | I = Discretionary transaction in accordance with Rule 16b-3(f) | J = Other | L = Small acquisition under Rule 16a-6 | M = Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | O = Exercise of out-of-the-money derivative security | P = Open market or private purchase | S = Open market or private sale | U = Disposition pursuant to a tender of shares in a change of control transaction | W = Acquisition or disposition by will or the laws of descent and distribution | X = Exercise of in-the-money or at-the-money derivative security | Z = Deposit into or withdrawal from voting trust |
 |
Send to Excel |
© 2000 - 2025 Zacks Investment Research